15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering NeoGenomics Inc, 6 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $8.00 to $25.00 (about 3.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $13.86 sits 3% above the current $13.42. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.05 next quarter toward $0.37 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Moderate Buy
Strong Buy00%
Buy675%
Hold225%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to NeoGenomics Inc.
As of Jul, 6 of 6 firms rate NEO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NEO EPS & revenue forecast
EPS · NEXT QUARTER
$0.05
Range $0.03 – $0.09 · 11 analysts · +82% YoY
Next period, 11 analysts expect NeoGenomics Inc to earn $0.05 a share (range $0.03 – $0.09), versus $0.03 a year earlier. Full-year consensus is $0.18, growing to $0.37 the year after.
REVENUE · NEXT QUARTER
$205.8M
Range $204.6M – $207.1M · 11 analysts · +10% YoY
Revenue is expected to reach $205.8M (range $204.6M – $207.1M), +9.6% year-over-year. Full-year consensus is $800.4M, rising to $880.7M next year.
Top analysts covering NeoGenomics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NEO.
#1
Mike Matson
Needham · Rank #204
Buy
$15.00+11.8% to target
Overall win rate
31%
+ Follow
#2
Matthew Sykes
Goldman Sachs · Rank #226
Buy
$10.00-25.5% to target
Overall win rate
37%
+ Follow
#3
David Westenberg
Piper Sandler · Rank #227
Buy
$13.00-3.1% to target
Overall win rate
31%
+ Follow
#4
Bruce Jackson
Benchmark · Rank #317
Buy
$11.00-18.0% to target
Overall win rate
35%
+ Follow
#5
Puneet Souda
Leerink Partners
Buy
$25.00+86.3% to target
Coverage
—
+ Follow
NEO stock forecast FAQ
What is NEO's average 12-month price target?+
The 7 analysts with a live target average $13.86 for NeoGenomics Inc over the next 12 months, ranging from a $25.00 high to a $8.00 low.
Is NEO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 8 analyst ratings, 6 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NEO?+
The Street-high target is $25.00 (Leerink Partners), and the Street-low is $8.00 (Morgan Stanley). The average of all 7 active targets is $13.86.
How many Wall Street analysts cover NEO?+
8 analysts have an active rating on NeoGenomics Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering NEO?+
Among analysts who currently cover NEO, Mike Matson of Needham has the strongest overall Quantellect track record (Rank #204). Their current call is Buy with a $15.00 target.
What is NeoGenomics Inc's projected EPS for next quarter?+
The consensus estimate is $0.05 per share (range $0.03 – $0.09) across 11 analysts. Full-year EPS is projected at $0.18, rising to $0.37 the following year.
How much revenue is NeoGenomics Inc expected to report next quarter?+
Consensus revenue is $205.8M (range $204.6M – $207.1M). Full-year revenue is projected at $800.4M, growing to $880.7M next year.
Have analysts been upgrading or downgrading NEO lately?+
As of Jul, 6 of 6 firms rate NEO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NEO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
